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Abstract
Dominant mutations in the promoter region of the mouse agouti gene lead to a
syndrome characterized by agouti yellow coat color, obesity, hyperinsulinemia,
hyperglycemia, type II diabetes and increased linear growth. The mechanism of agouti
modulation of the coat color development as well as obesity involves competitive
antagonism of the ? -melanocortin stimulating hormone at its receptor.
Hyperplasia of the pancreatic ? cells in agouti mice precedes the development of
obesity. Enhanced insulin secretion is induced in vitro by agouti effects on calcium influx
into islet cells. Preliminary testing of insulin producing pancreatic cells has shown that
exposure to high doses of an immunosuppressive drug tacrolimus (FK506) altered the
secretion of insulin. The hypothesis of the present study is that FK506 treatment of
transgenic mice, which either overexpress the agouti gene ubiquitously or in the adipose
tissue, may alter expression of agouti mRNA and protein. Agouti mice also have an
impairment of the immune system thus, another hypothesis to be tested was if
immunosuppression by FK506 would amplify the agouti phenotype.
There was decrease in food intake and glucose levels in the aP2 mice with
Tacrolimus (FK506). There was no detection of agouti mRNA or protein in adipose or
pancreatic tissue of wild type mice and no significant effect of FK506 on agouti mRNA or
protein expression in the aP2 mice. Toxic effects of FK506 at this dose in both mice were
not significant.
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I.

INTRODUCTION

Background and Characterization of the Agouti Mou se:
The melanocyte is the principal cell type involved in coat color pigmentation.
During embryonic development melanocyte precursors (melanoblasts) migrate from the
neural tube to the base of developing hair follicles (Billingham and Silvers, 1960; Searle
1968). The melanoblasts differentiate into melanocytes and function as unicellular glands
by secreting melanin granules into actively growing hair shafts (Billingham and Silvers,
1960). Eumelanin (brown or black color) and phaeomelanin (yellow or reddish) are two
distinct types of melanin produced by melanocytes (Searle1968).
Production of eumelanin and phaeomelanin in the mouse are regulated by the
agouti locus on chromosome2. Melanocytes produce eumelanin at first, then switch to
phaeomelanin synthesis and return to eumelanin production before the hair growth process
is complete which give rise to the true wild -type coat color of mice (agouti pigmentation)
(Galbraith, 1964). This pigmentation pattern is called agouti; hair of agouti mice are black
or brown at the tip with a subapical band of yellow, and black or brown at the base
which give animal an overall grizzled appearance (Searle1968).
Most of the coat colors genes act in a cell-autonomous manner within the
melanocyte but agouti usually function s within the microenvironment of the hair follicle.
Regulation of the coat color by agouti occurs through direct or indirect intracellular
signaling within the follicular environment. There are at least 20 dominant and recessive
agouti alleles form a com plex dominance hierarchy. Alleles associated with increased
1

phaeomelanin production are generally dominant over alleles associated with agouti
pigmentation, which in turn, are dominant over alleles primarily associated with eumelanin
production (reviewed in Silver 1979).
The mouse agouti gene was cloned and shown to encode a distinctive 131 amino
acid protein with a consensus signal peptide (Michaud et. al., 1993). A human homologue
of the mouse agouti gene was cloned that is 85% identical to the mouse agouti gene and
80% identical at the amino acid level (Kwon et. al., 1994; Wilson et. al., 1995). The
murine agouti gene is normally expressed only in the neonatal skin, where it regulates
melanocyte pigment production. A dominant mutation in the promoter region results in
ubiquitous expression of normal agouti protein throughout life in Ay agouti mice.

This

overexpression leads to a syndrome characterized by yellow coat color as well as obesity,
hyperinsulinemia, type II diabetes and an increased incidence of spontaneous and induced
tumors (Michaud et. al., 1994).
Mechanism of Agouti Signaling:
The mechanism by which the agouti protein alters function of melanocytes has
been well documented while the mechanism by which it causes obesity is not completely
understood and there are two different hypothesis for agouti action. The first hypothesis is
based on the opposing interactions between agouti and the 13 amino acid peptide ? melanocyte stimulating hormone (? -MSH). The hormone (? -MSH) causes melanocytes to
switch from the synthesis of phaeomelanin to eumelanin (Geschwind et. al., 1966). This
effect of ? -MSH is regulated through a Gs-coupled seven transmembrane domain receptor
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(Mountjoy et. al., 1992). ? -MSH is the natural ligand for MC1-R, MC3-R, MC4-R and
MC5-R. MC1-R (melanocyte-stimulating hormone receptor) is expressed in melanocytes
and has a physiological role in pigmentation (Mountjoy et. al., 1992). Level of cAMP is
elevated when ? -melanocyte stimulating hormone binds to its receptor (MC1-R). This
results in a switch from eumelanin (black pigmentation) to phaeomelanin (yellow
pigmentation) production (see fig 1). This competitive antagonism of melanocortin binding
serves as a paradigm for agouti action in obesity (Huszar et. al., 1997, reviewed in
Moussa-Moustaid Naima 1999).

Agouti

? -Melanocytes
Stimulating
Hormone

Melanocortin
receptor-1

Adenylyl Cyclase
(cAMP)

cAMP

Switch
eumelanin

phaeomelanin

Figure 1: Switch from Eumelanin to Phaeomelanin.
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MC3-R is found in hypothalamic and limbic systems MC4-R is expressed in the
brain, and is considered to regulate feeding behavior and metabolism (Dinulescu et. al.,
2000). Agouti protein has higher affinity for MC4-R than MC3-R. Antagonism of these
melanocortin receptors (MC3-R or MC4-R) could be responsible for the metabolic effects
of agouti gene. Deletion of MC4-R gene in mice leads to the development of
obesity/hyperinsulinemia (Tota et. al., 1998, Huzar et. al., 1997). In addition, intracerebro-ventricular administration of an MC4-R agonist inhibits feeding (Fan et. al.,
1997).
The cysteine-rich C-terminal region of agouti protein has the ? -MSH antagonism
property (Willard et. al., 1995). Yellow coat color in the dominant agouti mutation is
likely to be mediated through antagonism of the ? -MSH receptor, preventing the higher
level of intracellular cAMP to switch from phaemelanin to eumelanin pigment production
(Lu et. al., 1994).
A second hypothesis is that agouti protein binds to its own receptor and interferes
with the action of ? -MSH at an intracellular level (Conklin and Bourne, 1993). The agouti
receptor might couple to another G protein to inhibit adenylate cyclase, or affect other
intracellular messengers like calcium. This two-receptor hypothesis for agouti gene action
has important implications for the multiple roles of overexpressed agouti protein in
obesity, hyperinsulinemia and increased tumor susceptibility (Yen et. al., 1994).
Agouti protein and agouti related protein (Agrp) or agouti related transcript
(ART) are similar in structure and function, but different in the pattern of distribution
(Dinulescu and Cone, 2000). Agrp is usually expressed at the higher levels in the arcuate
4

nucleus and acts as the endogenous antagonist of the melanocortin 3 and 4 receptors
(MC3-R and MC4-R) (Stanley et. al., 1999). The hypothalamus of the rodent brain
expresses agouti related transcript (ART) (Shutter et. al., 1997). The hypothalamus of the
obese mice also expresses higher levels of ART and obesity is caused by the over
expression of ART in transgenic mice (Ollmann et. al., 1997). Human ART gene (human
agouti related protein or hAGRP) can bind and antagonize the hMC3-R and hMC4-R with
high affinity compared to MC1-R and MC5-R. It is thought that Agrp functions as a
natural antagonist of the neural MC3-R and MC4-R to regulate feeding behavior (Tota et.
al., 1998).
Relationship of Agouti to Other Obesity Genes (Leptin):
OB protein which is also known as leptin, is secreted by adipose tissue (Frederich
et. al., 1995). Leptin usually circulates in blood and binds to its family of binding proteins
and acts on central neural networks that regulate feeding behavior and energy balance.
This protein appears to play an important role in control of body fat stores through the
regulation of feeding behavior, metabolism, autonomic nervous system and body energy
balance (Campfield et. al., 1996). It is secreted and synthesized by adipose tissue in
proportion to adipocyte size and number. Like the agouti C terminal region, OB protein
also has a C terminal disulfide bond, which appears to play an important role in its activity
(Zhang et. al., 1994). OB protein binds to OB-R receptor, which are found to be
expressed in the choroid plexus, hypothalamus as well as several peripheral tissues and are
localized particularly in adipocytes, macrophages, stomach, placenta and pancreatic islet
cell type. There are several forms of OB- receptors, the short form (with a truncated
5

intracellular domain) and the long form (with the complete intracellular domain) are the
two major forms of the receptor (Campfield et. al., 1996). The long form of the receptor is
thought to be the signaling protein that has the biological effects (Tartaglia et. al., 1995).
Agouti regulates adipocyte metabolism including lipogenesis (Jones et. al. 1996)
and lipolysis (Xue et. al., 1998). Expression of agouti in adipose tissue increases both
adipose tissue and circulating plasma leptin levels (Claycombe et. al., 2000). Leptin
synthesis and secretion by agouti was increased due to the increase in leptin mRNA
content by agouti and not due to agouti-melanocortin receptor antagonism (Claycombe et.
al., 2000). Regulation of an obesity gene product by another obesity gene product and
metabolic hormones suggests that these interactions may play an important role in obesity
syndromes (Campfield et. al., 1996).
Diabetes, Hyperinsulinemia, and Agouti:
Intracellular calcium ?(Ca2+)i?

plays an important role in metabolic disorders

including obesity and insulin resistance (Draznin et. al., 1987). There is increase in basal
?(Ca2+)i? in adipocytes of obese patients (Xue et.al.,1998). Increases in ?(Ca2+)i? inhibits
insulin stimulated glucose transport. Ca2+-channel antagonism improves cellular insulin
sensitivity (Draznin 1993), which may play an important role in insulin resistance by
inhibiting the dephosphorylation of insulin sensitive targets. This includes glycogen
synthase and the insulin sensitive glucose transporter, which are activated by ?(Ca2+)i? induced phosphorylation and activation of inhibitor 1 through blocking the activation of
phosphoserine phosphatase 1 (Begum et. al., 1993). It is possible that ?(Ca2+)i? increases
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the activity of protein kinase C that may contribute to insulin resistance via
phosphorylation of the insulin receptor ? subunit tyrosine kinase (Bollag et. al., 1987).
Kim et.al. (1997) conducted a study to determine the effect of purified agouti
protein on ?(Ca2+)i? in cultured using skeletal myocytes, smooth muscle cells, adipocyte
cell lines, as well as in primary human adipocytes, to determine if these effects are
mediated through melanocortin receptors. Results suggested that agouti regulation of
?(Ca2+)i? in various tissues requires expression of melanocortin receptors.
Studies have shown intracellular Ca2+ to play an important role in the metabolic
disorder of obesity and insulin resistance (Byyny et. al., 1992, Draznin et. al., 1987).
Recombinant agouti protein causes a dose-dependent increase in ?(Ca2+)i? in variety of
cells including both murine and human adipocytes. Agouti protein stimulates the
expression and activity of fatty acid synthase, a key enzyme in deno vo lipogenesis, and
increases triglyceride accumulation in 3T3 L1 adipocytes in a Ca2+ dependent manner
(Jones et. al., 1996).
This result can also be observed by the stimulation of Ca2+ influx by KCl and
inhibited by a Ca2+ channel blocker (Xue et. al., 1999). The relationship between [(Ca2+)i]
and insulin signal transduction is not well understood. It seems that elevation in [(Ca2+)i]
may result in insulin resistance by affecting the phosphorylation of glucose transporter
type 4 and other insulin-sensitive substrates within the cell (Kim et. al., 1997).

7

Agouti and Pancreatic Function :
Obesity increases the risk of diabetes and 80% of type II diabetes are obese, but
not all diabetic people are obese and not all obese people are diabetic (Salan 1987).
Obesity and diabetes are influenced by independent factors (Barrett-Connor 1989). Obese
people have defective glucose tolerance but do not progress to a diabetic state because
both insulin resistance and ? -cell defects are required for type II diabetes in mice.
Transgenic mice expressing agouti in adipose tissue under the control of adipocyte specific
promoter (aP2 promote) become obese if supplemental insulin is concomitantly provided.
However supplemental insulin does not produce this effect in their nontransgenic
littermates (Mynatt et. al., 1997). Development of obesity in agouti mutant mice may be
due to hyperplasia of pancreatic ? cells. Hyperinsulinemia may be a direct effect of agouti
action on the pancreas and this hyperinsulinemia, combined with adipocyte agouti
expression, may contribute to the obesity syndrome in agouti mutants. This was confirmed
in vitro in cultured adipocytes where insulin and agouti exert additive effectson the FAS
gene. Insulin resistance is a special feature in type II diabetes and is a characteristic of
agouti mutant mice (Xue et. al., 1999).
Agouti mice exhibit some suppression of their immune system. The
immunosuppressive drug Tacrolimus (FK506) was used to see if this drug altered the
physiologic phenotype of these mice.

8

II.

IMMUNOSUPPRESSIVE DRUGS
Allogeneic (graft between the animal of same species) transplantation is made

possible by the use of immunosuppressive drugs. Three kinds of immunosuppressive drugs
are used in clinical transplantation.
1) Corticosteroids: are analogues similar to natural glucocorticoid hormone which
is produced by the adrenal cortex and have anti-inflammatory properties.
2) Cytotoxic drugs are commonly used in solid organ transplantation, these drug
usually interfer with DNA replication, kill proliferating lymphocytes which are activated by
graft alloantigens.
3) The microbial products cyclosporine A, tacrolimus (FK506) and rapamycin
derived from different microbes are all potent immunosuppressive agents which act by
inhibiting the signaling pathway of T-cell activation.
During 1960s and 1970s, transplant physicians depended on a combination of
corticosteroids and cytotoxic drugs to prevent the rejection of transplanted organs. In the
early 1970’s, introduction of cyclosporine A (CsA) significantly improved the outcome of
organ and bone marrow allograft transplantation and advanced therapeutic options in
autoimmune diseases (Bierer et. al., 1993). FK506 appears to have a higher therapeutic
effect than CsA. FK506 has been used in clinical transplantation trials with encouraging
results (Migita et. al., 1999). FK506 and CsA are structurally and chemically unrelated
but their mechanism of action are similar. Both FK506 and CsA bind to cytoplasmic
peptidyl-prolyl isomerases, which are abundant in all tissue (Bierer et. al., 1993).
Cyclosporine binds to cyclophilin and FK506 binds to FK-binding protein (FKBP) (Zenke
9

et. al., 1993). Both complexes inhibit the same cytoplasmic serine/threonine phosphatase,
calcineurin, which is necessary for the activation, by dephosphorylation, of a T cellspecific transcription factor (Schwaninger et. al., 1993). This transcription factor, NF-AT,
is involved in the synthesis of interleukins by activated T-cells. They have a similar effect,
inhibiting the action of calcineurin on signal transduction pathways, in other hematopoietic
cells (Lyson et. al., 1993). Rapamycin a structural analog of FK506, inhibits cellular
function by different molecular mechanisms (Bierer et. al., 1993).
Tacolimus (FK 506):
FK506 (Tacrolimus or Prograf) was discovered in 1984 by scientists at Fujisawa
Pharmaceutical Co (Japan) in the fermentation broth of the filamentous bacterium,
Streptomyces tsukubaensis. It is a 23-member ring macrolide lactone (Kino et. al., 1987).
Chemically it is designated as 5, 6, 8, 11, 12, 13, 14 1,5, 16, 17, 18, 19, 24, 25, 26, 26qhexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)1-methylethenyl]14,16-dimethoxy-4, 10,12,18-tetremethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido [2,1-c]
[1,4] oxaazacyclotricosine-1, 7, 20, 21 (4H, 23H)-tetrone, monohydrate (Walsh 1998).
The chemical structure of tacrolimus is shown below fig 2 (Ivery and Weiler 1997).
It has an empirical formula of C44H69NO12.H2O and a molecular weight of
822.05. Tacrolimus is as white crystal or crystalline powder. It is practically insoluble in
water, freely soluble in ethanol, and very soluble in methanol and chloroform (Walsh
1998). Tacrolimus is an important therapeutic agents used in preventing graft rejection
during tissue transplantation. It prolongs the survival of the host and transplanted graft in
animal transplant models of liver, kidney, heart, bone marrow, small bowels and pancreas,
10

lung and trachea, skin, cornea and limb (Siekierka and Signal 1992). The pharmacokinetic
parameters of FK506 have been determined following intravenous and oral administration
in healthy volunteers, liver transplant, and kidney transplant patients. The whole blood
concentration

serves

as

the

more

appropriate

sampling

to

describe

FK506

pharmacokinetics rather than plasma concentration.
Mechanism of Action:
The immunosuppressant FK506 is an extremely potent inhibitor of T-lymphocyte
activation (Clipstone and Crabtree 1992). The exact mechanism of action is yet not known
(Negulescu et. al., 1994).

Studies have shown that the drug becomes active only when

bound to specific members of the FK506 binding protein receptors. The FK506- FK506
binding protein receptor complexes interact with a major component of the T-cell antigen
receptors signal transduction pathway, the calcium-calmodulin-dependent phosphoprotein

Figure 2: Structure of FK506.
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phosphatase calcineurin (Liu et. al., 1991). FK506, after binding with its binding protein
receptors, inhibits the phosphatase activity of calcineurin and prevents transcriptional
activation of the interleukin-2 gene (Tocci and Sigal 1992, Luo et. al., 1996). This result
in inhibition of the T-lymphocyte activation (i.e. immunosuppression) (Shibasaki et. al.,
1996). See figure 3.
Relationship to diabetes:
As a result of calcineurin inhibition, FK506 alters multiple biochemical processes in
a variety of cells besides lymphocytes. This may be the cause for its adverse side effects
including neurotoxicity, nephrotoxicity, diabetogenicity and gastrointestinal disturbances

T
Cell

Cytoplasmic Domain
(CD3)
T Cell

Inter Leukin 2
IL2

T Cell S

T Cell Go
T Cell G1

Tacrolimus
(FK506)

Differentiation
Proliferation

Figure 3: Inhibition of T-cell by FK506
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(Dumont 2000). One of the most common toxicity effects of FK506 is insulin-dependent
diabetes mellitus (Jindal et. al., 1997).
Pancreas contains about half a million islets of Langerhans that make the hormones
insulin, glucagon, and somatostatin (Thorens and Waeber 1993). Each islet cell functions
in such a manner that they make a single hormone: ? - cells make glucagon, ? cells make
insulin, and ? cells make somatostatin (Kuby 1994). Insulin is usually secreted from the
pancreas in response to the increased blood glucose level arising after a meal (Porte and
Pupo 1969). Insulin binds to the surface receptors and stimulates cells to take up glucose
and convert it into carbohydrates and fat (Kuby 1994). Destruction of certain insulinproducing cells of pancreas gives rise to insulin dependent diabetes mellitus (IDDM)
(Bach 1994).
Individuals with IDDM, have an autoimmune antibody and T-cells respond against
insulin, glutamic acid decarboxylase, and other specialized proteins of the pancreatic ?
cells. CD8 T cells specific for some ? cells proteins are thought to mediate ? -cell
destruction resulting in decreased insulin secreting cells (Robertson 1995). Individual
islets become successively infiltrated with lymphocytes, and as ? cells die the structures of
the islet degenerates (Porte and Kahn 1989).
FK506 is an immunosuppressive drug, which interrupts calcium-calmodulincalcineurin signaling pathway in T cells, blocking antigen activation of the T cell early
activation genes. It is thought that regulation of insulin gene expression in the ? cell
involves a calcium-signaling pathway and clinical use of FK506 has been associated with
insulin requiring diabetes mellitus (Lohmann et al., 2000).
13

Animal Model (Rats and Mice) Studies Showing Pathophysiological Changes:

Several studies in animal models have shown that the toxicity of FK506 is dosage
dependent. Studies in a adult rat model (Ishida et. al., 1997) showed that a high oral dose
of FK506 for 13 weeks uniformly induced histopathologic changes in several tissues,
including renal and pancreatic injuries. Cataracts were also observed in rats dosed orally
with FK506 5mg/kg/day, with an incidence of 25%, where as no cataract formation was
observed in the 0.2 or 1mg/kg/day groups. Biochemical parameters, such as sorbitol, Na+/
K+-ATPase, and glutathione in the lens of rat were also evaluated. Five mg/kg/day FK506
led to an increase of sorbitol and a decrease of reduced glutathione but did not affect the
Na+/ K+-ATPase activity of the lens. The higher dose of FK506 also gave a very high
incidence of neurotoxicity and nephrotoxicity.
FK506 is known to have diabetogenicity mediated through pancreatic injury, which
appears as vacuolation of islet cell in rats. High dosages (5mg/kg/day) of FK506 induced
an elevation of blood glucose association with glucose intolerance, and decreases of both
basal insulin level and insulin content in the pancreas. These changes were parallel with the
cataract development in this study. Diabetic parameters did not change in lower dosage
groups (Ishida et. al., 1997).
Murase et.al. (1991) studied lower dosage FK506 effects on

preventing

spontaneous autoimmune diabetes in the BB rat. BB rat is the experimental analogue of
human juvenile diabetes mellitus. The diabetes follows specific autoimmune destruction of
the ? -cells while leaving ? and ? -cells intact. Intragastric doses of FK506 were given at
1.0 mg/kg/day to 2.0 mg/kg/day in the BB rat treated group. Treatment was started at 30
14

days of age and continued for 90 days. Body weight and glycosuria were measured three
times a week. Administration of 2.0 mg/kg/day of FK506 completely prevented the
development of spontaneous diabetes in BB rat, and greatly reduced the characteristic
histopathologic changes in the pancreas. With a lower dose of FK506 (1.0 mg/kg) 15.7%
became diabetic and prevention of pancreatic injury was less complete. However, posttherapy relapse rate of diabetes by this dose was low. In the untreated group 75%
developed diabetes between the age of 70 and 103 days. This study showed that the
higher (2.0 mg/kg/day) dose had beneficial effects, which far outlasted the time of
treatment. There was no mortality in this study except for that caused by diabetes, and
toxic effects of FK506 at this dose were not noted except for a slight decreased rate of
weight gain (Murase et al, 1991).
Toxic and therapeutic effects of FK506 have also been noted in murine studies.
Wada et. al., (1991) showed that daily injection of 3.2mg/kg FK506 could protect a
BALB/c skin graft in C57BL/6 recipient mice as long as the drug was continued for up to
1 month. With lower dosage of 1mg /kg, some of the animals rejected the skin graft, while
higher doses of 5.6 mg/kg, some animals died with an intact skin graft.

The cause of

death and its relationship to the higher dose of FK506 was not reported.
In contrast a lower dosage or shorter time course of FK506 may be well tolerated
in mice and even protect transplanted ? -cells. As a potential protocol for inducing
tolerance to islets allografts, Fukuzaki et. al., (1995), showed that induction of tolerance
to islet allografts is possible with preoperative donor spleen cell injection and a short
course of FK506 treatment. BALB/c and B6 mice were used as a donor and recipients for
15

the islet. Islet cells were isolated by collagenase digestion method. These islets were
transplanted in the renal subcapsular space of STZ-induced diabetic mice (streptozocininduced diabetic mice). Hyperglycemia level of >300mg/dl was the criteria indicating that
rejection had taken place. Mice were treated for a long and short course of FK506 after
transplant. Long course treatment was for 4 weeks after islet transplantation with
intramuscular FK506 dosages of 1.0 or 3.2 mg/kg. Short-term injection of FK506 was at
a dose of 3.2 or 10 mg/kg intramuscularly for 3 days (days 0 to 2,3 to 5, 5 to 7) after
transplant. Significant numbers of recipient mice showed normoglycemia over 90 days
following a short course of FK506 treatment. A short course of FK506 treatment after
grafting

has

been

found

to

induce

tolerance,

avoiding

long

term

use

of

immunosuppressant. A second experiment was carried out on the timing of the donor
spleen cell injection (DSI) and FK506 in order to induce tolerance to islet allografts.
There was marked increase in the graft survival after a single injection of FK506 on day 3
and day 5 after DSI. From this experiment it was observed that there is a critical window
period for the DSI and FK506 treatment for inducing unresponsiveness. Induction of
tolerance is possible before transplantation by administration of donor antigen followed by
a short course of FK506 treatment.
Kai et.al. (1993) showed the preventive effect of a low dosage of FK506 on
autoimmune insulitis in non-obese diabetic mice.

These mice develop diabetes

spontaneously as result of an autoimmune response to beta cells in the pancreatic islets.
The mice were given FK506 intraperitonelly in a dose of 1.0 mg/kg, every other day, from
ages 2 to 12, 2 to 6, and 4 to 12 weeks, the incidence of insulitis and overt diabetes was
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monitored. Effects of FK506 on immune reactions to ? cells were also investigated by
using both syngeneic and allogeneic islet transplants. Treatment with FK506 in mice from
age 2 weeks completely prevented the onset of overt diabetes, and the incidence of
insulitis was reduced to less than 10% at age 30 weeks. However, treatment of mice with
FK506 from age 4 weeks was less effective in preventing insulitis and onset of diabetes. In
the case of islet transplantation, FK506 treatment of non obese diabetic (NOD) mice from
age 2 to 6 weeks prevented autoimmune responses both in syngeneic (tissue that have
identical genotype) islets and in allogeneic islets, which share the same H-2 antigen with
the nonobese diabetic mouse ( Kai et.al. 1993).
Hypothesis:
The hypothesis to be tested in this study is that immunosuppressive calcineurin
inhibitors such as FK506, might alter agouti mRNA and/or protein levels in adipose and
pancreatic tissues. FK506 could also antagonize signal transduction pathways elicited by
agouti protein, which are required for its effects on both tissues. In addition, this study
also seeks to determine if the hyper expression of agouti might amplify the pathogenic
effects of a nontoxic dosage of FK506.
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III.

MATERIALS AND METHOD

Animals:
Agouti mice (aP2) specifically express agouti in adipose tissue under the control of
the fatty acid binding promoter. Adipose tissue specific promoter agouti mice (aP2) along
with their nontrasgenic littermates were selected for this study. The expression of agouti in
aP2 mice is found in skin, white (higher level) and brown adipose tissue, muscle and low
levels in the pancreas (Mynatt et. Al., 1997). Male and female mice of four weeks to eight
weeks of ages and at least 20 grams of body weight were used in this study. They all were
caged in a clean environment with hepta-filtered air to protect the immunosuppressed
animals from pathogenic organisms. The mice used in this study were from the breeding
colony at the Department of Nutrition, University of Tennessee Knoxville. Each transgenic
strain and its normal littermates were divided into two groups housed in cages of 2 each.
Diet/Dosing Tacrolimus:
The mice were allowed free access to the powder diet (Dyets Inc. PA) of
10gm/day/ cage and water. The transgenic and nontransgenic littermates (treated groups)
were treated with FK506 oral dosage of up to 0.5-0.7mg/kg/day for 13 weeks by mixing it
with powder diet (0.05mg of FK506/10 gm diet). The plasma level of FK506 was assayed
by a modified enzyme immunoassay using a mouse monoclonal anti-FK506 antibody
(Abbott Diagnostic, Abbott Prk, IL). The calculated average dosage of FK506 of the
course of the study was about 0.7mg/kg/day based on the consumption of 3.3gm of food.
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This compares to the human therapeutic dose for immunosuppression of 0.02 mg/kg/day
(2 oral tablets/day).
Tissue Sampling:
After 13 weeks of treatment the mice were sacrificed. Immediately after sacrifice
fat pads abdominal, perirenal and subscapular fat pads were pooled, pancreas, kidney and
the head were collected. Fat and pancreas for the RNA extraction were kept in RNA Later
(Ambion, Austin, TX), which acts as a preservative for the RNA. Kidneys, a small portion
of the pancreas (50mg), and the head were preserved in Carson Millonig (10 % formalin,
sodium phosphate 14.7gm/L, sodium hydroxide 2.15/L) (Biochemical Sciences Inc,
Swedesbord, NJ) for the study of pathophysiological changes.
Body weight, Urinanalysis, Blood Glucose/Insulin Levels:
Body weight of the mice was measured at the time of treatment and weekly for 13
weeks. Weekly urinanalysis was done by a semiquantitative analysis strip (chemstrip 2GP
Roche Diagnostic Corporation, IN). Glucose detection is based on the enzymatic glucose
oxidase/ peroxidase method. A positive reaction is indicated by color change of the strips
from yellow to green.

The blood glucose level was measured at the time of initial

treatment and weekly by Fast Take Glucose Meter Test Strips from Life Scan Johnson and
Johnson Company. Blood was obtained by pricking the tail vein (Ishida et. al., 1997). At
the time of sacrifice, blood was obtained by cardiac puncture for blood glucose and
centrifuged at 1600g for 20 minutes. The plasma was used to determine the circulating
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insulin levels by rat insulin enzyme immunoassay kit (Cayman Chemicals, Ann Arbor, MI)
(Ishida et. al., 1997).
Other Pathophysiologic Changes:
Tissue were routinely fixed in Carson’s Millonig

(Biochemical Sciences Inc,

Swedesbord, NJ), processed, and paraffin-embedded. Histopathological examination of
the eye lenses, pancreas and kidney was done to determine any cataract formation,
amyloid deposition, or renal changes as evidence of nephrotoxicity in the treated mice as
compared to untreated controls.
RNA Preparation and RT-PCR:
Total RNA from adipose tissue and pancreas was prepared using CsCl density
centrifugation. Adipose and pancreatic tissues were taken out of the RNA Later solution
(Ambion) and weighed. Guanidine Thiocynate with ? -mercaptoethanol were added 10 ml
to 1 gram of tissue. The tissues (fat and pancreas) were homogenized using a tissue tearer
(Distributed by Brinkmann Co. made in Switzerland by Kinematics Gmbh) for 30 seconds.
The homogenized solution was gently layered over the cesium chloride (5ml) in 12ml
Sorvall tubes (Sorvall Instrument, Wilmington, DE). The tubes were balanced and sample
centrifuged at 40,000 rpm for 18-20 hours at 20oc in a Sorvall Rotor. The supernant was
aspirated and the RNA pellet at the bottom of the tube was dissolved in RNase free water.
RNA was quantitated by measuring its absorbance at 260/280 nm (UV Visible Recording
Spectorphotometer, Shimadza Corporation, Kyoto, Japan), and its quality was assessed
after electrophoresis of 3? g of RNA on a 1% agarose gels stained with ethidium bromide.
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Two distinct bands of 28s and 18s consistent with intact RNA were observed in
photographs of the gel.
RT-PCR was conducted as described by Kwon et. al., (1994) from the extracted
RNA. Construction of cDNA was done using 3? g/5? l of RNA in 50? l reaction. RNA
was heated at 650C for 5minutes and cooled in ice for 5 minutes. Reverse transcription
10x buffer, dNTP mixture, RNasin ribonuclease inhibitor, random hexamers and AMV
reverse transcriptase mix was added at last to the RNA. The cDNA reaction was
incubated at room temprature for 10 minute and heated at 420C for 60 minutes and at
990C for 5 minutes to inactivate AMV and on ice for 5 minutes (Perkin Elmer,
Branchburg, NJ). PCR was performed using red Taq polymerase (Sigma, Saint Louis,
MO). The conditions for PCR were 1 cycle (940C, 5 min), 35 cycles (940C, 30 s; 680C, 1
min; 720C, 1 min) with 0.5 ? M agouti sense (ATGGATGTCACCCGCCTAC) and agouti
antisense (CGCAGTTGGGGTTGAGTA) primers (Sigma Genosys, St. Louis, MO). ? actin primers ( Sigma, Genosys, St. Louis, MO ) were added to separate PCR reactions as
a control for the same cDNA product. The amplified PCR product was then visualized by
1% agarose gel electrophoresis (Kwon et. al., 1994). Autoradiogram results were
quantitated by video densitometry on a Lynx 4000 Molecular Biology Workstation
(Applied Imaging, Santa Clara, CA, USA). Expression of agouti cDNA was normalized to
those of ? -actin and expressed as a ratio of density of agouti bands over density of actin
bands in the same sample. ANOVA test was used for statistical analysis of the data.
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Northern Blot Analysis:
Northern blot was performed in the RNase free condition (Autoclave tips and tube,
DEPC treated water, and wearing gloves). Total RNA (20? g) from adipose and
pancreatic tissues for electrophoreses was prepared by adding 2.5? l sample loading buffer
(0.75ml formamide, 0.25ml formaldehyde, 0.15ml 10x MOPS [3-N (Morpholinol)
Propane Sulfonic Acid], 0.3 ml glycerol and 0.25% bromophenol blue) per 1? l of RNA
sample. Samples were heated at 65oC for 10 minutes then cooled in ice for 5 minutes then
electrophoresed through formaldehyde-agarose gels (1 gm of agarose in 74 ml of DEPC
treated water, 10 ml of 10x MOPS and 16 ml of 37% formaldehyde). RNA was
transferred from gels to the Gene Screen Plus Hybridization Transfer membrane (New life
Science, Boston, MA) by capillary transfer method. The membrane was placed in the UV
light cross linker chamber and cross-linked for 30 seconds 160mJ/cm2. The cross-linked
membrane was then stained with methylene blue (0.3M Na Acetate Ph 5.2 and 0.03%
methylene blue, treated with DEPC). If the 28s and 18s bands were visible, a picture of
the membrane was taken. The blot was pre hybridized with ULTRAhyb (Ambion, Austin,
TX) and hybridized with radiolabeled agouti probe. The probe was prepared by using
Random Primer DNA Labeling System (Gibco BRL life technologies, Gainshburg, MD).
After a high (2X SSC, 0.1% SDS) and low stringency (0.1X SSC, 0.1% SDS) wash the
blot was exposed to X-ray film for autoradiography. The blot was stripped in a boiling
solution of 0.1X SSC and 0.1% SDS for 15 minute with slight agitation. The process of
pre hybridization and hybridization was repeated again with a probe for the ? -actin as an
internal control to check the quantity and quality of RNA present (Yen et. al., 1994).
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Autoradiogram results were quantitated by video densitometry on a Lynx 4000 Molecular
Biology Workstation (Applied Imaging, Santa Clara, CA, USA). Expression of agouti
mRNA was normalized to those of ? -actin by dividing the density of agouti bands with the
density of actin bands in the same sample.
significant differences between

The normalized data was compared for

strains and treatments with using ANOVA statistical

analysis.
Western Blot Analysis:
The frozen tissue samples of adipose (100 mg) and pancreas (60mg) were weighed
and immediately sonicated in centrifuge tubes for 1 minute using a Vibra Cell Sonicator
Bath in 5? l/mg tissue of 1.5 fold concentrated denaturing mix (250 mM Tris HCl pH 6.8,
3% sodium dodecyl sulphate (SDS) 250mM EDTA, 250 mM EGTA, 0.015%
bromophenol blue, 15% glycerol) with 3% ? -mercaptoethanol. The samples were then
centrifuged for 40 minute at 150,000? g at 200C. Supernanant aliquots of 90? l were
electrophoresed through 6-17% SDS-PAGE gradient gels and transblotted to
nitrocellulose membranes according to standard methods. 1% nonfat milk proved superior
to 1% bovine serum albumin and was used to block nonspecific binding sites on the
nitrocellulose after protein transfer.

All washes and incubations with primary and

secondary antibodies were per manufacturer's directions (Enhanced Chemiluminescence
ECL Kit, purchased from Amersham). ECL detected bound antibodies with horseradish
peroxidase-conjugated goat anti-mouse immunoglobulin. The nitrocellulose membranes
were treated with rabbit anti mouse agouti (Alpha Diagnostic International, San Antonio,
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TX). The secondary antibody was horseradish peroxidase (HRP) conjugated goat anti
rabbit (Jackson Labs, West Groove, PA). Bound antibody was detected by Super Signal
West Pico Chemiluminescent Substrate (PIERCE, Rockford, IL). The blot was stripped
with stripping buffer (100mM 2-mercaptoethanol, 62.5mM Tris HCl pH 6.0 and 2% SDS)
and reprobed with mouse anti glyceraldehyde 3-phosphate dehydrogenase (Sigma, Saint
Louis, MO) and visualized with HRP-goat anti mouse IgG as internal control for loading
differences.
The band observed by the western blot was confirmed to be agouti by running the
same sample through the NuPage Bis-Tris Gels (Novex, San Diego, CA) and blotting it to
the PVDF Membrane (Novex, San Diego, CA). The membrane was stained with
Coomassie blue stain (25% isopropanol, 10% acetic acid and 0.05% Coomassie blue) and
destaining was done with several changes of 10% acetic acid plus 10% methanol solution.
The band observed at the level of 14 Kda, after destaining, was cut out and microsequenced in 494 Protein Sequence (Applied Biosystem, Foster, CA) with cycles and
conditions as recommended by the manufacture.
Data Analysis:
Computerized statistical analysis was performed on data by group comparisons to
determine significant differences. The criteria for parametric testing assume samples from
normally distributed populations with the same variances. This test is based on the
estimates of the population means and standard deviation, the parameters of a normal
distribution. Nonparametric tests do not assume samples from a normal population
distribution. Ranks Sum Tests automatically rank numeric data, and then compare the
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ranks rather than the original values. The parametric tests used in this study are unpaired ttests and ANOVA. Nonparametric tests are Mann-Whitney Rank Sum Test and KruskalWallis Analysis of Variance on Ranks. Chi-square or Fisher Exact test was performed to
analyze proportions for significant differences. The power or sensitivity, of the test is the
probability that the test will detect a difference or effect if there is a differences or effect.
Power of 0.80 means that there is an 80% chance of detecting a specified effect with 1-?
confidence (i.e,a 95% confidence when ? =0.05). The type of test for each data set is
indicated in the figure or table legend or in the text.
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IV.

RESULTS

FK506 plasma levels:
In a pilot study after 4 weeks of the diet supplemented with FK506, blood plasma
levels of FK506 in the treated (8) mice are 20 times higher than in treated human
(transplant patient). This assay was done to make sure that the diet with FK506 achieved a
high but nontoxic dosage of FK506. It was confirmed that the mice were taking the food
properly and the level of FK506 was high enough. Diet consumed averaged over the
treatment course by agouti mice was 3.35 gm and by the nontransgenic littermate is 3.45
gm/day. The average FK506 consumed by agouti treated mice was 0.67mg/kg/day and
treated wild type was 0.69mg/kg/day dose for each group
Diet:
Figure A-1 (agouti mice) and Figure A-2 (non transgenic littermates) shows the
average food intake per week by the mice throughout the treatment. Initially there was
significantly less food intake by both groups of FK506 treated mice, which became
insignificant by week 2. This is most likely the result of the mice becoming accustomed to
the taste of the FK506. Food uptake remained rather constant although low for the
treatment groups throughout the 13 weeks of treatment with no evidence of the expected
hyperphagia by the agouti mice. Surprisingly, at the end of the 13 weeks untreated non
transgenic littermates averaged less consumption (3gm P=0.001) as compared to the
beginning intake. There were also significant differences in the consumption of food in
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treated and untreated agouti mice at the end of the time course (treated ones 2.7gm P=
P=0.408 untreated 3.4gm P=0.001). Further studies over a longer time course would be
necessary to confirm these effects of FK506 on food intake.
Body Weight:
Figures A-3 (agouti) and A-4 (non transgenic littermates) shows weekly body
weight averages for FK506 treated and non-treated groups. Despite the slight reduction
in food intake over the course of the experiment, the nontransgenic littermates showed no
effect of FK506 treatment on weight gain. At the end of the treatment the agouti mice
showed significant differences with respect to FK506 treatment (Figure A-3). The
untreated agouti mice gained more weight as compared with the treated agouti (P=
0.020). This may be due to the overall less consumption of the food or an effect of the
drug on metabolism or fat deposition.
Blood Glucose Level:
Studies by Mynatt et. al. (1997) had shown that there are no differences in the
blood glucose level in the transgenic mice (aP2) 120 ? 7 and 122 ? 11 mg/dl non
transgenic littermates respectively. One of the toxic effects of FK506, established in the
rat model, is insulin dependent diabetes with attendant elevation of blood glucose due to
the injury of the pancreatic cells (Ishida et. al., 1997). Figures A-5 (agouti) and A-6 (nontransgenic littermates) show blood glucose levels (mg/dl), which were low in both the
treated and untreated mice at the beginning of the experiment. Which may reflect some
stress and acclimatization to a new environment or sampling error. By the second week,
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more normal values were seen for all groups with and without FK506 treatment. At the
third week of treatment with FK506, the agouti mice showed a significant and unexplained
decrease in the blood glucose level. This returned to normal by the fourth week and
remained relatively constant through out the rest of the time course. There is no significant
difference at the end of the time course in the blood glucose levels in the treated and
untreated groups with this dosage of FK506. The glucose levels were quite variable and
reached >200mg/dl in several of the untreated agouti mice. FK506 treated agouti mice
had less variable glucose levels and none >200 mg/dl. The high variability resulted in an
overall lack of a statistically significant effect of FK506 treatment and no evidence for a
diabetic effect.
Plasma Insulin Levels:
Plasma insulin levels were determined using the RIA kit per manufacturer's
directions. Data obtained is shown in Table I. Statistical analysis showed that that mean
values of the treated mice (agouti mice 0.187 ? 0.0221nmols/ml and wild type 0.220 ?
0.0131nmols/ml, P=0.761) were less than untreated agouti mice 0.200 ? 0.0344nmols/ml
or wild type 0.230? 0.069nmols/ml, P=0.122). Plasma insulin level of the agouti and the
wild type mice with FK506 are 31? 3? U/ml, 36? 2? U/ml, respectively. Those without
FK506 treatment had insulin levels of: agouti mice 33? 5? U/ml and wild type 38?
11? U/ml. Previous studies of plasma insulin level of the aP2 at 25 to 30 weeks were found
to be 29? 8? U/ml for transgenic mice and 31? 8? U/ml for nontransgenic littermates
(Mynatt et. al.1997).
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Urinanalysis:
None of the mice showed color change in strips showing that the urine glucose
level were in normal range in both treated and untreated agouti mice and their non
transgenic littermates.
RT-PCR:
RT-PCR products with agouti primer (Figure A-7) from adipose and pancreatic
tissues showed expression of the agouti mRNA in both treated and untreated agouti mice.
There was no detectible expression of the agouti in corresponding tissue from non
transgenic littermates (Figure A-8) with or without FK506. PCR done with the same
cDNA sample with ? actin showed a band for each sample after agarose gel
electrophoresis (Figure A-9).

Data was analyzed by densitometery for RT-PCR and

normalized as mean ? SE of agouti/? -actin densitometry (arbitrary units) for 10 treated
versus 10 untreated mice from the aP2 or nontransgenic littermates. The expression of the
agouti cDNA in the adipose and pancreatic tissues in the aP2 with and without FK506 was
0.628± 0.168SD (treated) versus 0.587±0.161 (untreated) (P=0.708) and pancreas 1.140±
0.727SD (treated) versus 0.493±0.172 (untreated) (P=0.089). Wild type mice with and
without FK506 showed no detectable expression of agouti cDNA in the adipose and the
pancreatic tissues.
Northern Blot:
Northern blot analysis of RNA from adipose (Figure A-9) and pancreatic (Figure
A-10) tissues of FK506 treated and untreated agouti mice show no difference in the
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expression of the agouti. There was no expression of agouti in the treated wild type mice
(Figure A-11, A-12). ? -actin northern analysis of these blots showed similar amounts of
RNA within each experiments. Data was analyzed as the normalized mean ? SE of
agouti/? -actin densitometry (arbitrary units) for 10 treated versus 10 untreated mice from
the aP2 or nontransgenic littermates. The expression of the agouti mRNA in adipose tissue
of the aP2 mice with and without FK506 was 1.152? 1.188 SD versus 1.069? 0.686 SD
(P=0.851) respectively and for pancreas 1.550? 1.214 SD versus 3.019? 3.092 SD
(P=0.179) respectively. Adipose and pancreatic tissues of wild type mice, either with or
without FK506, showed no detectable expression of the agouti mRNA and therefore no
difference in expression of agouti with FK506 treatment could not be evaluated. We can
only conclude that high dosages of FK506 had no effects on the adipose or pancreatic
tissue levels of agouti mRNA in the aP2 agouti mice.
Western Blot:
Several attempts at western blotting to analyze agouti protein levels were carried
out.

SDS solubilized tissue fractions were electrophoresed on SDS PAGE and

transblotted by standard protocols as described in Methods. Blocking with bovine serum
albumin gave multiple non specific bands which were reduced by using 1% non-fat milk.
Expression of the agouti peptide in fat was seen in agouti mice with and without FK506.
In view of multiple bands observed, even with 1% non-fat milk, micro-amino acid
sequencing the N-terminal sequence 131amino acids of blot bands was used to confirm
that the 14.5 kDa band was the agouti peptide and that other higher molecular weights
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band were unrelated. The candidate agouti band was sequenced at least 3 times from the
treated and untreated agouti and gave a match to the known sequence for agouti. Despite
several attempts at varying extractions and SDS-PAGE transblotting conditions and use of
two different antibody preparations for agouti (monoclonal antibody, affinity pure
monoclonal antibody from Alpha Diagnostic International, San Antonio, TX) the results
were quite variable with problems of nonspecific and variable specific staining making data
analysis difficult.

Analysis of 3-phospho-glyceraldheyde dehydrogenase (GAPDH) was

done to determine equal loading and blotting efficiency. No marked differences were
observed in agouti protein levels in FK506 treated mice. As expected, there was no
detectable agouti band or amino acid sequence in the 14.5 kDa region SDS-PAGE
analysis of wild type mice fat and pancreatic tissue. This is consistent with the RT-PCR
and northern blotting results for agouti mRNA. We were also unable to detect agouti
peptide in the pancreatic tissue of agouti mice.
Histopathology:
Histopathological study of the pancreatic islet cells was limited. There were four
groups of mice; each group had ten mice (treated and untreated) but we did not obtain
usable sections on all these mice because of the requirements of tissue for the other
studies. Islet cells of six agouti mice with FK506 and four without FK506 were observed.
Of 552 total cells observed in agouti mice treated with FK506, 19% were vacuolated. Of
the 259 cells observed in agouti without FK506 treatment, significantly fewer 5.9% (Chisquared test, p < 0.001) cells were vacuolated. Islet cells of two wild type mice with and
without FK506 (non transgenic littermates) were observed. Of 81 total cells observed in
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wild type mice with FK506, 38% cells were vacuolated and without FK506 of 95 total
cells a statistically similar number (p = 0.949, Chi-square test) (38%) was observed to be
vacuolated. Figure A-14 (A and B) shows typical examples of vacuolation of the islet cells
in the treated and non-treated mice. Unexpectedly the agouti mice had significantly less
vacuolation than their nontransgenic wild type littermates either with or without treatment
(p < 0.001). These results suggest some general protective effect of the agouti protein on
islet cell.
It had been reported in rats that high 5mg/kg/day dosages of FK506 uniformly
caused cataract formation (Ishida et. al., 1997). Studies were done to detect cataract
formation after the 0.7mg/kg/day dose FK506 treatment in this study examining 10 agouti
mice and 10 nontransgenic littermates. Mild cataracts were observed in two treated agouti
mice, Figure A-15 (A). Cataracts were not observed in their littermates, Figure A-15 (B),
but this was not statistically significant (Fisher Exact test, p = 0.474).
It had also been reported that high doses of FK506 had toxic effects on the kidney
with histopathologic changes in glomerulus tissue. In this study, no apparent kidney
pathology was observed in either of the FK506 treated groups of mice (data not shown).
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V.

DISCUSSION
The purpose of this study was to determine if a high but nontoxic dose of the

immunosuppressive drug FK506 alters expression of the agouti gene message and/or
protein as well as the agouti phenotype. Conversely, this study sought to determine if
overexpression of agouti enhanced or altered the toxic effects of FK506.
Mice carrying agouti mutation are expected to exhibit increased body weight
compared to their littermate as early as 4 weeks of age (Dicki et. al., 1946, Roberts et. al.,
1984). At three months of age, mice overexpressing agouti show approximately twofold
increase in body weight compared to control mice (Frigeri et. al., 1988). The obese yellow
mice (Avy and ? actin agouti mice) are moderately hyperphagic and eat 10-36% more
than the lean littermates (Frigeri et. al., 1988, Yen et. al., 1976). There were no such
changes observed in our study with either strain of transgenic and nontransgenic mice with
or without FK506 treatment.
At the end of the time course, body weight and blood glucose levels of agouti mice
with and without FK506 show significant differences (P= 0.020, P=0.010). Body weight
and the blood glucose levels of the untreated agouti mice tended to be higher than the
treated ones. A previous study in rats has shown that there is reduction of body weight
gain in the 5mg/kg/day FK506 treated animals, which is reversible (Ishida et. al., 1997).
Hyperinsulinemia and hyperplasia of pancreatic ? -cells leads the development of
obesity in agouti mutant mice with ubiquitous overexpression of agouti (Warbritton et. al.,
1994). Intracellular calcium also plays an important role in the metabolic disorder of
obesity and insulin resistance (Byyny et. al., 1992, Draznin et. al., 1988). While
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hyperinsulinemia is detectable at 4 weeks of age in ob/ob mice, Avy/A (BALB/ c ? VY)
F1 mice become hyperinsulinemic after 6 weeks of age and exhibit a sexual dimorphism as
well as hyperglycemia. By 2 months of age, plasma insulin concentration in yellow Avy/a
mice were 4-fold those of controls in females and, 10-fold those of a/a control mice in
males (Yen et. al., 1990).
Studies have shown that aP2 mice only become markedly obese with daily
injection of insulin. The combination of agouti expression in adipose tissue and insulin
treatment induced physiological changes which result in body weight gain similar to other
transgenic strains of mice, like BAP20 (? -actin promoter), which ubiquitously express
agouti. BAP20 mice are obese and plasma insulin levels are elevated at the age of 12
weeks (Mynatt et. al. 1997).
In this study, plasma insulin level of the agouti mice with FK506 treatment was
lower than untreated agouti mice (0.377? 0.222, 0.640? 0.344) but the observed changes
were not significant. Of note, FK506 treatment reduced insulin levels in the aP2 but not
wild type mice and the reduced levels were comparable to the untreated or treated wild
type mice.
FK506 has been associated with insulin dependent diabetes mellitus during clinical
use (Redmon et. al., 1996). FK506 is known to cause diabetogenicity through pancreatic
injuries (Ishida et. al., 1997).

It has been shown that high dosage (5mg/kg/day) causes

the pancreatic injury, which appears as vacuolation of islet cells in rats (Ishida et. al.,
1997). In this study, an unexpected difference in vacuolation between the agouti and
normal littermates was observed along with a possible protective effect of agouti
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overexpression on preventing FK506 toxicity at this lower dose.

However, FK506

toxicity in terms of islet cell vacuolation was not observed in the treated versus untreated
wild type mice.
It has been reported (Ishida et. al., 1997) that histopathological examination
revealed rupture along with swollen and liquefacient lens fiber in rats treated with high
dose of FK506. No pronounced toxic effect of a lower dose of FK506 was observed
histopathologically in either aP2 agouti or wild type mice in this study.
The Northern blot and PCR results indicate that there is no effect of FK506 in both
strains of mice and limited western blot showed similar result.
The agouti gene is expressed from two different promoters, one active at the
midpoint of the hair cycle and other specific for the ventrum, is responsible for generating
pigmentation pattern. During the embryonic whisker plate transcript from the hair cycle
are detected but before birth it is not detected in other regions of the body, ventral-specific
transcripts are detected in the ventral trunk of the embryo and ventral whisker plate. It
suggests that agouti gene is regulated by two factors responsible for establishing
differences between the dorsal and ventral surfaces of the body during embryogenesis. aP2
mice express very high level of agouti in brown and white adipose tissue. These mice show
normal insulin level and do not become obese. This suggests that expression of agouti in
adipose tissue is not enough for the mice to be obese ( Mynatt et. al., 1997 reviewed
Moustaid-Moussa 2000). Daily injection of insulin leads to increases in body weight, so
agouti may interact with insulin to induce obesity by upregulating lipogenesis in
adipocytes. Signaling pathways that lead to increases in lipogenesis or activation of the
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lipogenic genes by insulin are not known yet. It has been shown that PI 3 kinase signaling
pathway, but not the P70 S6 kinase nor the MAP kinase pathway, mediate insulin effect
on FAS (Fatty Acid Synthase) (Dong and Hei 1998). None of these studies have shown
whether the calcinuerin pathway is also involved in adipose tissue/agouti promoter
regulation.
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VI.

FUTURE DIRECTIONS
There was decreased food intake and blood glucose level in aP2 mice this

may be due to FK506. There was no detection of agouti mRNA or protein in adipose or
pancreatic tissue of the wild type mice but agouti was expressed in both tissue of agouti
mice. There was no significant effect of FK506 on agouti mRNA or protein expression in
the aP2 mice. No significant toxic effect of FK506 at this dosage was observed in both
mice.
In future work treatment should be done with other mice strains or rat model for a
longer time period. However, there are no rat models overexpressing agouti available.
Alternatively, the same model could be tested with different method of treatment
(intraperitoneal or intragastric) or higher doses. However, in this study a relatively high
dosage of FK506 was used which achieved a 20 fold higher than therapeutic dose as
confirmed by analysis of blood levels relative to transplant patients. Another possibility
would be to analyze agouti expression in human patient population if suitable tissue
sampling and analytical assays could be worked out. Transplant patients using
immunosuppressive drug could then be examined for a possible agouti relationship to
immunosuppression and human immune cell function. This might expand on the finding of
an immune dysfunction in the overexpressing agouti strains.
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Figure A-1. Powder Diet Consumed by Agouti Mice with and without FK506

10 grams of powder food with and without FK506 was poured in each container daily.
Food consumption of mice was measured every day. Weight of the consumed food was
obtained by subtracting the weight of the container with remaining food and weight of the
empty container. Statistical analysis was performed on the data by ANOVA group
comparisons. Lines with triangle represent the agouti mice with FK506 and circles
represent without FK506. At the beginning of the treatment there was significant difference
(figure A-1) (P=0.008) in consumption of food and the untreated mice consistently
consumed more food throughout the time course of the study. The difference was not
statistically significant at the end of the treatment time course compared to treated and
untreated (P=0.083).
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Figure A-2. Powder Diet Consumed by Wild Type with and without FK506
10 grams of powder food with and without FK506 was poured in each container daily.
Food consumption of mice was measured every day. Weight of the consumed food was
obtained by subtracting the weight of the container with remaining food and weight of the
empty container. Statistical analysis was performed on the data by ANOVA group
comparisons. Lines with triangle represent the wild type mice with FK506 and circles
represent without FK506. At beginning of the treatment there was significant difference
(figure A-2) (P=0.001) in food consumption. However, no differences in food consumption
were observed by the end of the treatment compared to treated and untreated (P=0.878).
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Figure A-3. Body weight of Agouti Mice with and without FK506
Body weight of the mice was taken weekly. Statistical analysis was performed on the data
by group comparisons by ANOVA test. At the beginning both groups of mice started with
the same weight (P=0.553). By the end of the time course, untreated mice had gained more
weight than the FK506 treated mice (P= 0.020).
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Figure A-4. Body weight of Wild Type with and without FK506
Body weight of the mice was taken weekly. Statistical analysis was performed on the data
by group comparisons by ANOVA test. At the beginning both mice groups started with no
statistically significant difference in weights (P=0.194). At the end of the treatment time
course there were no significant differences observed in the weights of the treated vs
untreated mice (P= 0.419)
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Figure A-5. Blood Glucose Level of the Agouti Mice with and without FK506
The blood glucose level was checked weekly in fed mice by using glucometric strips with
blood obtained by pricking the tail vein. Data is plotted as average blood glucose +/- SD.
Average blood glucose levels were higher and more variable for the untreated mice
throughout the time course of treatment. Statistical analysis of the data done at the
beginning of the treatment P=0.214 and at the end of treatment P=0.134 showed no
significant effect of the FK506 treatment.
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Figure A-6. Blood Glucose Level of the Wild Type with and wit hout FK506
The blood glucose level was checked weekly in fed mice using glucometric strips with blood
obtained by pricking the tail vein. Data is plotted as average blood glucose +/- SD. The
average blood glucose levels in the treatment group were lower throughout the time course.
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Figure A-7. RT-PCR of cDNA from the Fat and Pancreatic Tissue of the Agouti Mice
and their Littermates.
RT-PCR products were size-fractionated in agarose gels and stained with ethidium bromide.
First lane indicates the size in bp of the 100bp ladder molecular weight marker. Remaining
lane is the 0.4Kb fragment is amplified using oligonucleotide primer specific for agouti.
Second lane is the positive control, from three to seven lanes is PCR product of the fat
tissue with FK506 and remaining lane eight to twelve is without FK506. The 0.8Kb
fragment, amplified using oligonucleotide primers specific for the actin mRNA, serves as a
positive control. Panel A RT-PCR of RNA from adipose tissue: Agouti mice and their non
transgenic littermates with and without FK506. Panel B Shows RT-PCR of RNA from
pancreatic tissue: Agouti mice and their non transgenic littermates with and without FK506.
Oligonucleatide primer specific for agouti. Oligonucleatide primer specific to actin. On the
left hand side of the Panel A and B band with an arrow is 0.5Kb and those with the line is
0.4Kb and 0.8Kb.
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Figure A-8. Northern Blot Analysis for Fat Tissue of Agouti Mice with and without
FK506
The agouti cDNA was

32

P-labeled and hybridized to poly (A)+RNA (20? g per lane) from

the fat tissue with and without FK506. Upper panel five treated and untreated and lower
panels five treated and untreated mice. The first lane from the left is the positive control of
agouti; lane two to six is the RNA from the fat tissue with FK506. Remaining lanes (seven
to eleven) are the ones without FK506. The nylon membrane was again hybridized with
actin to see the quality and quantity of the extracted RNA. Data are presented as the mean ?
SE of Agouti/? -actin for ten treated and untreated mice. There is no difference in the
expression of the Agouti in adipose in treated and untreated (P= 0.851).
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Figure A-9. Northern Blot Analysis of Pancreatic Tissue of Agouti Mice with and

without FK506
The agouti cDNA was 32P-labeled and hybridized to poly (A)+RNA (20? g per lane) from
the pancreatic tissue with and without FK506. Upper panel five treated and untreated and
lower panels five treated and untreated mice. The first lane from the left is the positive
control, two to six lanes is the RNA from the fat tissue with FK506. Remaining lanes (seven
to eleven) are the ones without FK506. The nylon membrane was again hybridized with
actin to see the quality and quantity of the extracted RNA. Data are presented as the
mean? SE of Agouti/? -actin for ten treated and untreated mice. There is no difference in the
expression of the agouti in pancreas from the treated and untreated mice (P = 0.179).
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Figure A-10. Northern Blot Analysis of Fat Tissue of Wild Type with and withou t
FK506
The agouti cDNA was 32P-labeled and hybridized to poly (A)+RNA (20? g per lane) from
the fat tissue with and without FK506. Upper panel five treated and untreated and lower
panels five treated and untreated mice. The first and last lane for upper panel is the positive
control for agouti two to six lane is the RNA from the fat tissue with FK506, seven to
eleven lane is RNA from fat without FK506. First lane of lower panel is positive control two
to six lane is the RNA from fat tissue with FK506 and the remaining lane is without FK506.
The nylon membrane was again hybridized with actin to observe the quality and quantity of
the extracted RNA. Data are presented as the mean? SE of Agouti/? -actin for ten treated
and ten untreated mice. Statistical analysis (P=0.149).
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Figure A-11. Northern Blot Analysis of Pancreatic Tissue of Wild Type with and
without FK506
The agouti cDNA was 32P-labeled and hybridized to poly (A)+RNA (20? g per lane) from
pancreatic tissue with and without FK506. Upper panel five treated and untreated and lower
panels five treated and untreated mice. The first lane is the positive control, two to six lanes
is the RNA from the pancreatic tissue with FK506, and seven to eleven lane is without
FK506. There is no expression of the agouti in treated and untreated ones. The nylon
membrane was again hybridized with actin to see the quality and quantity of the extracted
RNA. Data are presented as the mean? SE of Agouti/? -actin for ten treated and ten
untreated mice. Statistical analysis (P=0.450).
.
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Figure A-12: Western Blot Analysis of the Fat Tissue of Agouti Mice with and
without FK506
The frozen fat tissue was treated with 1.5 fold concentrated denaturing buffer and the
sample ultracentrifuged to remove insoluble. The extract is loaded on the gradient gel and a
western blot with rabbit anti mouse agouti was performed. The first lane is the low
molecular weight marker; second lane is the positive control. From lane three to seven is
with FK506 and lane nine to twelve is without FK506, which shows no differences in the
expression of the peptides.
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Figure A-13: Western Blot Analysis of the Fat Tissue of Wild Type Mice with and
withou t FK506
The frozen fat tissue was treated with 1.5% denaturing buffer, the sample was
ultracentrifuged to remove the insoluble. The extract is loaded in the gradient gel and a
western blot with rabbit anti mouse agouti was performed. The first lane is the low weight
molecular marker; lane second is the positive control. From lanes three to seven lane is with
FK506 and lane nine to twelve lane is without FK506, which shows no differences in the
expression of the peptides.
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Figure A-14: A Cut Section o f the islet cells of the agouti and their nontrasngenic
littermates with and without FK506.
Vacuolation of the islet cells are present in both treated and untreated subjects.
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Figure A-15: A Cut section of the eye (lens).
A. shows an irregular pattern with swollen lens fiber cells large vacuoles in the subcapsular
cortex. B. normal eye lens.
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Appendix B: Table
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Table 1. Plasma Glucose Level of the Agouti Expressed Mice and their Littermates
with and without FK506

Blood was collected at the time of sacrifice by heart puncture; plasma was collected by
centrifugation. Plasma glucose level was measured using EIA kit. Statistical analysis shows
the (P=0.761 of the treated mice and untreated P=0.122) mean plasma glucose value of the
treated mice are significantly lower than those of the untreated ones.
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Mice

Mean

Std
Dev

SEM

Ag With
FK506

0.187 nmol/ml

0.221

0.0698

Ag Without
FK506

0.220 nmol/ml

0.0131

0.109

Wild Type with
FK506

0.200 nmol/ml

0.0344

0.01414

Wild Type
without FK506

0.230 nmol/ml

0.069

0.0532
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